Graphite Bio
Graphite Bio raises $238M Series B at $1B valuation
Graphite Bio: Series B Funding Round
Graphite Bio has successfully raised $238M in Series B funding, reaching a valuation of $1B.
Company Overview
Precision genetic medicines
Funding Details
The Series B round was led by ARCH Venture Partners, with participation from Vida Ventures, Norwest Venture Partners, Samsara BioCapital.
Company Information
- Headquarters: 279 East Grand Avenue, South San Francisco, CA 94080
- Founded: 2019
- Employees: 150+
- Category: Biotech
Investment
Graphite Bio plans to use the funds to accelerate product development, expand its team, and scale operations globally.
About the Investors
- ARCH Venture Partners: Verified investor in Series B
- Vida Ventures: Verified investor in Series B
- Norwest Venture Partners: Verified investor in Series B
- Samsara BioCapital: Verified investor in Series B
Company Info
Investors (4)
Share
Related Reports
AusperBio Raises $73M Series B
Biotech company developing AHB-137, an antisense oligonucleotide for chronic hepatitis B treatment entering phase 2 trials
Orna Therapeutics Raises $251M Series B
Biotechnology company developing circular RNA therapeutics for cancer, genetic diseases, and infectious diseases
Forge Biologics Raises $120M Series C
Gene therapy CDMO providing manufacturing and development services for AAV-based genetic medicines
Turn your sales ideas into reality today
Start your 14-day Pro trial today. No credit card required.
Start building for free